SciClone’s Zadaxin For Hepatitis C Rises From Ashes
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III interim data has positive implications for twice-failed drug, analyst and SciClone CEO tell "The Pink Sheet" DAILY.